MedPage Today on MSN4d
Add-On Cemiplimab Shows Promise as First-Line Treatment for Penile CancerSAN FRANCISCO -- A combination of cemiplimab (Libtayo) and standard-of-care chemotherapy appeared to be effective in patients ...
Regeneron UK Limited has announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo (cemiplimab) for use on ...
Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...
TuHURA Biosciences, a biotech firm, is advancing DNA-based immunotherapy for cancer. Read what warrants a Hold rating for ...
Study shows that Libtayo plus chemotherapy has lower cost and a larger effect on improving quality-adjusted life years than ...
News Medical on MSN6d
Scottish Medicines Consortium approves Libtayo as second-line treatment for advanced cervical cancerRegeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...
The cancer vaccine market is anticipated to experience substantial growth in the coming years. This growth is driven by the rising number of cancer diagnoses, heightened awareness of cancer vaccines, ...
Scottish Medicines Consortium approves Libtayo as second-line treatment for advanced cervical cancer
The acceptance of cemiplimab by the SMC marks the availability of the first immunotherapy for recurrent or metastatic cervical cancer on or after platinum-based chemotherapy, irrespective of PD-L1 ...
Infusion reactions that can sometimes be severe or life-threatening. Signs and symptoms of infusion reactions may include: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback